Celldex Therapeutics [CLDX] vs Arcutis [ARQT] Detailed Stock Comparison

Celldex Therapeutics

NASDAQ

Arcutis

NASDAQ

TLDR: Quick Comparison Summary

Based on 18 vital metrics comparison: Celldex Therapeutics wins in 6 metrics, Arcutis wins in 11 metrics, with 0 ties. Arcutis appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric	Celldex Therapeutics	Arcutis	Better
P/E Ratio (TTM)	-9.17	-13.78	Arcutis
Price-to-Book Ratio	2.23	13.78	Celldex Therapeutics
Debt-to-Equity Ratio	0.46	79.27	Celldex Therapeutics
PEG Ratio	-0.16	0.20	Celldex Therapeutics
EV/EBITDA	-3.61	-22.64	Arcutis
Profit Margin (TTM)	0.00%	-35.40%	Celldex Therapeutics
Operating Margin (TTM)	-8,747.53%	-17.93%	Arcutis
Return on Equity	-27.18%	-57.33%	Celldex Therapeutics
Return on Assets (TTM)	-19.08%	-13.46%	Arcutis
Free Cash Flow (TTM)	$-159.70M	$-117.30M	Arcutis
1-Year Return	-39.57%	62.56%	Arcutis
Price-to-Sales Ratio (TTM)	252.55	7.27	Arcutis
Enterprise Value	$834.97M	$1.81B	Arcutis
EV/Revenue Ratio	144.21	6.88	Arcutis
Gross Profit Margin (TTM)	N/A	90.81%	N/A
Revenue per Share (TTM)	$0	$2	Arcutis
Earnings per Share (Diluted)	$-3.01	$-0.73	Arcutis
Beta (Stock Volatility)	1.22	1.85	Celldex Therapeutics

Performance

Key Stats

Valuation

Financials

Short Interest

Dividends

Celldex Therapeutics vs Arcutis Stock Performance Analysis

Loading Price Chart...

Performance Comparison

Short-term Returns

Stock	1D	1W	1M	3M	6M	YTD
Celldex Therapeutics	2.00%	-11.92%	0.45%	10.26%	5.30%	-12.91%
Arcutis	1.23%	-5.39%	9.83%	16.98%	28.97%	9.75%

Long-term Returns

Stock	1Y	3Y	5Y	10Y	15Y	20Y
Celldex Therapeutics	-39.57%	-28.68%	87.17%	-90.25%	-66.43%	-90.55%
Arcutis	62.56%	-34.67%	-35.04%	-26.70%	-26.70%	-26.70%

Performance Comparison

This comparison requires JavaScript for dynamic charts and real-time data. For complete performance analysis, visit the individual stock overview pages:

Celldex Therapeutics (CLDX): View Full Stock Overview

Arcutis (ARQT): View Full Stock Overview

The individual stock overview pages contain detailed performance metrics, historical charts, financial data, and comparison tools that work without JavaScript.

Key Performance Metrics Available:

Daily, weekly, monthly, and yearly returns
52-week high and low prices
Market capitalization and valuation ratios
Financial health and profitability metrics
Dividend history and yield information

Performance & Financial Health Analysis: Celldex Therapeutics vs Arcutis

Metric	CLDX	ARQT
Market Information
Market Cap i	$1.46B	$1.92B
Market Cap Category	Small cap	Small cap
10 Day Avg. Volume i	1,726,940	1,685,733
90 Day Avg. Volume i	1,155,657	1,680,894
Last Close	$22.46	$15.98
52 Week Range	$14.40 - $47.00	$8.03 - $17.75
% from 52W High	-52.21%	-9.94%
All-Time High	$3,375.00 (Mar 06, 2000)	$40.88 (Mar 16, 2020)
% from All-Time High	-99.33%	-60.91%
Growth Metrics
Quarterly Revenue Growth	-0.71%	1.64%
Quarterly Earnings Growth	-0.71%	1.64%
Financial Health
Profit Margin (TTM) i	0.00%	-0.35%
Operating Margin (TTM) i	-87.48%	-0.18%
Return on Equity (TTM) i	-0.27%	-0.57%
Debt to Equity (MRQ) i	0.46	79.27
Cash & Liquidity
Book Value per Share (MRQ)	$9.87	$1.16
Cash per Share (MRQ)	$9.49	$1.59
Operating Cash Flow (TTM) i	$-186,190,000	$-65,492,000
Levered Free Cash Flow (TTM) i	$-110,811,752	$-53,092,124
Dividends
Last 12-Month Dividend Yield i	N/A	N/A
Last 12-Month Dividend i	N/A	N/A

Valuation & Enterprise Metrics Analysis: Celldex Therapeutics vs Arcutis

Metric	CLDX	ARQT
Price Ratios
P/E Ratio (TTM) i	-9.17	-13.78
Forward P/E i	-6.82	-16.31
PEG Ratio i	-0.16	0.20
Price to Sales (TTM) i	252.55	7.27
Price to Book (MRQ) i	2.23	13.78
Market Capitalization
Market Capitalization i	$1.46B	$1.92B
Enterprise Value i	$834.97M	$1.81B
Enterprise Value Metrics
Enterprise to Revenue i	144.21	6.88
Enterprise to EBITDA i	-3.61	-22.64
Risk & Other Metrics
Beta i	1.22	1.85
Book Value per Share (MRQ) i	$9.87	$1.16

Financial Statements Comparison: Celldex Therapeutics vs Arcutis

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)	CLDX	ARQT
Revenue/Sales i	$695,000	$65.85M
Cost of Goods Sold i	N/A	$8.83M
Gross Profit i	N/A	$57.02M
Research & Development i	$52.61M	$17.54M
Operating Income (EBIT) i	$-62.74M	$-24.53M
EBITDA i	$-70.82M	$-18.67M
Pre-Tax Income i	$-53.80M	$-24.78M
Income Tax i	N/A	$279,000
Net Income (Profit) i	$-53.80M	$-25.06M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)	CLDX	ARQT
Cash & Equivalents i	$17.14M	$53.10M
Total Current Assets i	$693.76M	$323.67M
Total Current Liabilities i	$32.02M	$91.13M
Long-Term Debt i	$1.93M	$109.96M
Total Shareholders Equity i	$702.98M	$142.66M
Retained Earnings i	$-1.61B	$-1.15B
Property, Plant & Equipment i	$8.12M	$3.34M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)	CLDX	ARQT
Operating Cash Flow i	$-45.24M	$-25.82M
Capital Expenditures i	$-265,000	$-608,000
Free Cash Flow i	$-54.64M	$-30.99M
Debt Repayment i	N/A	N/A
Common Stock Repurchase i	N/A	N/A

Short Interest & Institutional Ownership Analysis

Metric	CLDX	ARQT
Shares Short i	7.78M	16.64M
Short Ratio i	8.06	10.75
Short % of Float i	0.14%	0.17%
Average Daily Volume (10 Day) i	1,726,940	1,685,733
Average Daily Volume (90 Day) i	1,155,657	1,680,894
Shares Outstanding i	66.37M	117.85M
Float Shares i	53.21M	85.58M
% Held by Insiders i	0.00%	0.02%
% Held by Institutions i	1.12%	1.09%

Dividend Analysis & Yield Comparison: Celldex Therapeutics vs Arcutis

Metric	CLDX	ARQT
Last 12-Month Dividend i	N/A	N/A
Last 12-Month Dividend Yield i	N/A	N/A
3-Year Avg Annual Dividend i	N/A	N/A
3-Year Avg Dividend Yield i	N/A	N/A
3-Year Total Dividends i	N/A	N/A
Ex-Dividend Date	N/A	N/A

Celldex Therapeutics [CLDX] vs Arcutis [ARQT] Detailed Stock Comparison